Evidence map›Paper›PMID 41641047›Full record

ArticleFrontiers in public health2025

Proton beam therapy induces protective immunity via HMGB1-dependent signaling.

Jialing Wen, Xuanzhang Tu, Wangcai Ren, Qiaojuan Wang, Yue Wang, Gang Guo, Kensuke Osada, Takashi Shimokawa, Akihisa Takahashi, Nakako Izumi Nakajima and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Jialing Wen *Department of Nuclear Physics, China Institute of Atomic Energy, Beijing, China.
Xuanzhang Tu *Department of Nuclear Physics, China Institute of Atomic Energy, Beijing, China.
Wangcai RenCollege of Physics and Optoelectronic Engineering, Shenzhen University, Shenzhen, China.
Qiaojuan WangDepartment of Nuclear Physics, China Institute of Atomic Energy, Beijing, China.
Yue WangDepartment of Nuclear Physics, China Institute of Atomic Energy, Beijing, China.
Gang GuoDepartment of Nuclear Physics, China Institute of Atomic Energy, Beijing, China.
Kensuke OsadaInstitute for Quantum Medical Science, National Institutes for Quantum Science and Technology (QST), Chiba, Japan.
Takashi ShimokawaInstitute for Quantum Medical Science, National Institutes for Quantum Science and Technology (QST), Chiba, Japan.
Akihisa TakahashiGunma University Heavy Ion Medical Center, Maebashi, Gunma, Japan.
Nakako Izumi NakajimaQST Hospital, National Institutes for Quantum Science and Technology (QST), Chiba, Japan.
Shenke ZhangDepartment of Gastroenterology and Hepatology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, Henan, China.
Wenchao GuDepartment of Artificial Intelligence Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan.
Yang LiDepartment of Radiation Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Chen LiChina CDC Key Laboratory of Radiological Protection and Nuclear Emergency, National Institute for Radiological Protection, Chinese Center for Disease Control and Prevention, Beijing, China.
Li SuiDepartment of Nuclear Physics, China Institute of Atomic Energy, Beijing, China.
Liqiu MaDepartment of Nuclear Physics, China Institute of Atomic Energy, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Proton beam therapy is widely regarded for its cost-effectiveness, precision, and protection of normal tissues. Emerging evidence shows that conventional radiotherapy can inhibit primary tumors and promote immunogenicity of distant tumors, possibly via damage-associated molecular patterns (DAMPs) like calreticulin (CRT) and high mobility group box 1 (HMGB1) released during immunogenic cell death (ICD). However, the role of proton beams in inducing DAMPs and enhancing immunogenicity remains unclear. This study aimed to investigate the effects of proton beam-induced DAMPs on the colonization of distal tumors. In this study,

Indexed as

Colonic NeoplasmsHMGB1 ProteinProton TherapySignal TransductionAnimalsCalreticulinCell Line, TumorImmunogenic Cell DeathMiceMice, Inbred BALB CCalreticulinHMGB1 ProteinHMGB1 protein, mousecalreticulinhigh mobility group box 1immunogenic cell deathproton beam radiationtumor colonization rejection

Identifiers

PMID41641047
PMCPMC12865983

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.